Odyssean LLC Takes Position in Medpace Holdings, Inc. $MEDP

Odyssean LLC bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, Holdings Channel.com reports. The fund bought 6,361 shares of the company’s stock, valued at approximately $3,369,000. Medpace makes up approximately 0.5% of Odyssean LLC’s holdings, making the stock its 12th biggest holding.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Medpace during the second quarter valued at $1,323,047,000. AQR Capital Management LLC lifted its stake in Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after purchasing an additional 324,293 shares in the last quarter. Wasatch Advisors LP lifted its stake in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Medpace by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Medpace by 18.9% during the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. TD Cowen lifted their target price on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. Robert W. Baird raised their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Truist Financial upped their price objective on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $595.20.

Insider Activity

In other news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the transaction, the director directly owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. This represents a 15.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 134,471 shares of company stock valued at $82,151,311 over the last ninety days. 20.50% of the stock is owned by corporate insiders.

Medpace Price Performance

NASDAQ:MEDP opened at $591.29 on Friday. The firm has a market capitalization of $16.50 billion, a price-to-earnings ratio of 34.66, a PEG ratio of 2.65 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The business has a 50 day simple moving average of $574.67 and a 200-day simple moving average of $499.52.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.